Table 4.

Antitumor activity of APLs and APL prodrugs.

Compound	IC50 (μM)
	A549	H292	16HBE
Miltefosine	77 ± 15	70 ± 9	73 ± 8
M12	46 ± 11	56 ± 7	107 ± 14
ME12	39 ± 7	52 ± 28	69 ± 26
M${}_{{\text{E}}^{\prime }12}$	139 ± 32	59 ± 10	49 ± 6
MC12	151 ± 42	81 ± 29	62 ± 15
M${}_{{\text{C}}^{\prime }12}$	48 ± 15	146 ± 37	66 ± 27
MC18:1	92 ± 22	135 ± 41	50 ± 12
Perifosine	127 ± 39	77 ± 3	116 ± 33
P12	56 ± 7	63 ± 5	72 ± 7
PE12	139 ± 4	168 ± 7	231 ± 70
P${}_{{\text{E}}^{\prime }12}$	148 ± 38	116 ± 25	60 ± 5
PC12	89 ± 24	73 ± 17	82 ± 33
P${}_{{\text{C}}^{\prime }12}$	189 ± 52	295 ± 33	145 ± 34
PC18:1	273 ± 69	186 ± 42	207 ± 49
Erufosine	57 ± 8	46 ± 8	19 ± 3
E12	81 ± 7	124 ± 11	225 ± 31
EE12	151 ± 42	125 ± 26	144 ± 66
E${}_{{\text{E}}^{\text{′}}12}$	192 ± 44	73 ± 15	63 ± 7
EC12	161 ± 21	167 ± 56	252 ± 112
E${}_{{\text{C}}^{\prime }12}$	179 ± 63	161 ± 25	257 ± 81
EC18:1	326 ± 36	154 ± 40	238 ± 58

The IC₅₀ values were determined in various cell lines exposed to the compounds for 24 h at 37°C, using the MTT assay. Data for erufosine and erufosine prodrugs are reported from the literature (Gaillard et al., 2019).